ChemoMetec A/S (LON:0DZ0)

Market Cap	1.11B
Revenue (ttm)	50.96M
Net Income (ttm)	18.75M
Shares Out	n/a
EPS (ttm)	1.08
PE Ratio	59.31
Forward PE	44.10
Dividend	0.45 (0.08%)
Ex-Dividend Date	Oct 11, 2024

Volume	242
Average Volume	673
Open	548.75
Previous Close	548.50
Day's Range	540.50 - 550.23
52-Week Range	340.60 - 613.50
Beta	n/a
RSI	55.14
Earnings Date	Sep 11, 2025

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1997
• Employees: 174
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0DZ0

Financial Performance

In 2024, ChemoMetec's revenue was 407.87 million, a decrease of -8.22% compared to the previous year's 444.40 million. Earnings were 136.28 million, a decrease of -23.72%.

Financial numbers in DKK